Stent having non-woven framework containing cells

Details Stent having non-woven framework containing cells Stent having non-woven framework containing cells

2005-07-05

2005-07-05

Naff, David M. (Department: 1651)

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Implant or insert

C424S093700, C435S176000, C435S180000, C435S395000, C435S398000, C435S402000

Reexamination Certificate

active

06913762

ABSTRACT:
Implantable medical devices that include a non-woven framework are described, as well as methods of using such devices to deliver therapeutic compounds to a patient.

REFERENCES:
patent: 3692618 (1972-09-01), Dorschner et al.
patent: 4060081 (1977-11-01), Yannas et al.
patent: 4340563 (1982-07-01), Appel et al.
patent: 4856516 (1989-08-01), Hillstead
patent: 4973493 (1990-11-01), Guire
patent: 4979959 (1990-12-01), Guire
patent: 4992226 (1991-02-01), Piez et al.
patent: 4994081 (1991-02-01), Civerchia et al.
patent: 5002582 (1991-03-01), Guire et al.
patent: 5007934 (1991-04-01), Stone
patent: 5030233 (1991-07-01), Ducheyne
patent: 5034352 (1991-07-01), Vit et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5217492 (1993-06-01), Guire et al.
patent: 5258041 (1993-11-01), Guire et al.
patent: 5263992 (1993-11-01), Guire
patent: 5274074 (1993-12-01), Tang et al.
patent: 5312380 (1994-05-01), Alchas et al.
patent: 5324647 (1994-06-01), Rubens et al.
patent: 5567612 (1996-10-01), Vacanti et al.
patent: 5643580 (1997-07-01), Subramaniam
patent: 5670161 (1997-09-01), Healy et al.
patent: 5690670 (1997-11-01), Davidson
patent: 5693085 (1997-12-01), Buirge et al.
patent: 5723003 (1998-03-01), Winston et al.
patent: 5725567 (1998-03-01), Wolff et al.
patent: 5817126 (1998-10-01), Imran
patent: 5824043 (1998-10-01), Cottone, Jr.
patent: 5824049 (1998-10-01), Ragheb et al.
patent: 5830879 (1998-11-01), Isner
patent: 5861032 (1999-01-01), Subramaniam
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5957972 (1999-09-01), Williams et al.
patent: 6004943 (1999-12-01), Shi et al.
patent: 6054288 (2000-04-01), Selden et al.
patent: 6063101 (2000-05-01), Jacobsen et al.
patent: 6080177 (2000-06-01), Igaki et al.
patent: 6090618 (2000-07-01), Parmacek et al.
patent: 6096070 (2000-08-01), Ragheb et al.
patent: 6102887 (2000-08-01), Altman
patent: 6156373 (2000-12-01), Zhong et al.
patent: 6348069 (2002-02-01), Vacanti et al.
patent: 6455283 (2002-09-01), Ferrara et al.
patent: WO 97/37617 (1997-10-01), None
patent: WO 00/10620 (2000-03-01), None
Andreansky et al., “The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors,”Proc. Natl. Acad. Sci. USA,1996, 93:11313-11318.
Bhatnagar et al., “The Role in Cell Binding of a β-bend within the Triple Helical Region in Collagen α1(I) Chain: Structural and Biological Evidence for Conformational Tautomerism on Fiber Surface,”J. Biomolecular Structure&Dynamics,1997, 14(5):547-560.
Bhatnagar et al., “Design of Biomimetic Habitats for Tissue Engineering with P-15, a Synthetic Peptide Analogue of Collagen,”Tissue Engineering,1999, 5:53-65.
Felgner et al., “Enhanced Gene Delivery and Mechanism Studies with a Novel Series of Cationic Lipid Formulations,”J. Biol. Chem.,1994, 269(4):2550-2561.
Fletcher et al., “A steroid-triggered switch in E74 transcription factor isoforms regulates the timing of secondary-response gene expression,”Proc. Natl. Acad. Sci. USA,1997, 94:4582-4586.
Kay et al., “Gene therapy,”Proc. Natl. Acad. Sci. USA,1997, 94:12744-12746.
Lai et al., “Intercellular delivery of a herpes simplex virus VP22 fusion protein from cells infected with lentiviral vectors,”Proc. Natl. Acad. Sci. USA,2000, 97(21):11297-11302.
No et al., “Ecdysone-inducible gene expression in mammalian cells and transgenic mice,”Proc. Natl. Acad. Sci. USA,1996, 93:3346-3351.
Simari et al., “Requirements for Enhanced Transgene Expression by Untranslated Sequences from the Human Cytomegalovirus Immediate-Early Gene,”Mol. Med.,1998, 4:700-706.
Smith et al., “Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice,”Nat. Genet.,1993, 5:397-402.
Spector and Samaniego, “Construction and Isolation of Recombinant Adenoviruses with Gene Replacements,”Meth. Mol. Genet.,1995, 7:31-44.
Stadler et al., “Do Cultured Vascular Smooth Muscle Cells Resemble Those of the Artery Wall? If Not, Why Not?”J. Cardiovasc. Pharmacol.,1989, 14(Suppl. 6):S1-S8.
Su et al., “Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart,”Proc. Natl. Acad. Sci. USA,2000, 97:(25):13801-13806.
Uchida et al., “HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1human hematopoietic stem cells,”Proc. Natl. Acad. Sci. USA,1998, 95:11939-11944.

Affiliated with

Also associated with

Rating

Stent having non-woven framework containing cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stent having non-woven framework containing cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stent having non-woven framework containing cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3386797